# EDGAR Filing Document

**Accession Number:** 0000771999
**File Stem:** 0001641172-25-025258
**Filing Date:** 2025-8
**Character Count:** 14047
**Document Hash:** db0098381bcab917d73ec9c04438a8b3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-025258.hdr.sgml**: 20250822

**ACCESSION NUMBER**: 0001641172-25-025258

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250822

**DATE AS OF CHANGE**: 20250822

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DSS, INC.
- **CENTRAL INDEX KEY:** 0000771999
- **STANDARD INDUSTRIAL CLASSIFICATION:** PAPERBOARD CONTAINERS & BOXES [2650]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 161229730
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-50256
- **FILM NUMBER:** 251247175

**BUSINESS ADDRESS:**
- **STREET 1:** 275 WIREGRASS PKWY
- **CITY:** WEST HENRIETTA
- **STATE:** NY
- **ZIP:** 14586
- **BUSINESS PHONE:** 585 232 1500

**MAIL ADDRESS:**
- **STREET 1:** 275 WIREGRASS PKWY
- **CITY:** WEST HENRIETTA
- **STATE:** NY
- **ZIP:** 14586

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DOCUMENT SECURITY SYSTEMS INC
- **DATE OF NAME CHANGE:** 20030326

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NEW SKY COMMUNICATIONS INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** THOROUGHBREDS USA INC
- **DATE OF NAME CHANGE:** 19861118
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chan Heng Fai Ambrose
- **CENTRAL INDEX KEY:** 0001261725

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 2601 INSLAND PLACE TOWER
- **STREET 2:** 510 KINGS RD N POINT
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999999999

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHAN FAI
- **DATE OF NAME CHANGE:** 20030828

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 21)**

**DSS, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.02 per share**

*(Title of Class of Securities)*

**26253C201**

*(CUSIP Number)*

**Heng Fai Ambrose Chan**<br>9 Temasek Boulevard #16-04, Suntec Tower<br>Singapore U0 038989<br>011 65 6333 9181

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/20/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **26253C201** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Heng Fai Ambrose Chan** | Name of reporting person<br>**Heng Fai Ambrose Chan** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**U0** | Citizenship or place of organization<br>**U0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**6730059.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**6730059.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6730059.00** | Aggregate amount beneficially owned by each reporting person<br>**6730059.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**69.6%** | Percent of class represented by amount in Row (11)<br>**69.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) The beneficial ownership of Heng Fai Ambrose Chan includes 6,730,059 shares of common stock, consisting of (a) 1,002,978 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Ambrose Chan; (b) 1,184,475 shares of common stock held by Heng Fai Ambrose Chan directly; (c) 311,634 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited; (d) 2,581,268 shares of common stock and debt convertible into 581,395 shares of common stock held by Alset Inc.; and (e) 1,068,309 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc. (2) Based on 9,092,518 shares of the common stock of the Issuer outstanding as of August 21, 2025.

| **CUSIP No.** | **26253C201** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Alset Inc.** | Name of reporting person<br>**Alset Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4542606.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4542606.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4542606.00** | Aggregate amount beneficially owned by each reporting person<br>**4542606.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**47.0%** | Percent of class represented by amount in Row (11)<br>**47.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** (1) Includes 2,581,268 shares of common stock and debt convertible into 581,395 shares of common stock held directly by Alset Inc.; 311,634 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited; and 1,068,309 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc. (2) Based on 9,092,518 shares of the common stock of the Issuer outstanding as of August 21, 2025.

| **CUSIP No.** | **26253C201** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Global Biomedical Pte. Ltd.** | Name of reporting person<br>**Global Biomedical Pte. Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**U0** | Citizenship or place of organization<br>**U0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**311634.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**311634.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**311634.00** | Aggregate amount beneficially owned by each reporting person<br>**311634.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.4%** | Percent of class represented by amount in Row (11)<br>**3.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Based on 9,092,518 shares of the common stock of the Issuer outstanding as of August 21, 2025.

| **CUSIP No.** | **26253C201** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Alset International Limited** | Name of reporting person<br>**Alset International Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**U0** | Citizenship or place of organization<br>**U0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1379943.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1379943.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1379943.00** | Aggregate amount beneficially owned by each reporting person<br>**1379943.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.2%** | Percent of class represented by amount in Row (11)<br>**15.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Based on 9,092,518 shares of the common stock of the Issuer outstanding as of August 21, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.02 per share

**(b) Name of Issuer:**
DSS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
275 Wiregrass Pkwy,, West Henrietta, NY, 14586

**Item 4. Purpose of Transaction**

On August 20, 2025, the Issuer issued a convertible promissory note (the "Convertible Note") to Alset Inc. in the amount of $500,000.00. Under the terms of the Convertible Note, Alset Inc. may convert outstanding principal and interest into shares of the Issuer's common stock at a conversion price of $0.86 per share.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Heng Fai Ambrose Chan: 6,730,059, 69.6% Alset Inc.: 4,542,606, 47.0% Global Biomedical Pte. Ltd.: 311,634, 3.4% Alset International Limited: 1,379,943, 15.2%

**(b)**
Heng Fai Ambrose Chan: 6,164,664 Alset Inc.: 4,542,606 Global Biomedical Pte. Ltd.: 311,634 Alset International Limited: 1,379,943

**(c)**
None.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Heng Fai Ambrose Chan

**Signature:** /s/ Heng Fai Ambrose Chan

**Name/Title:** Heng Fai Ambrose Chan, an Individual

**Date:** 08/22/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Alset Inc.

**Signature:** /s/ Heng Fai Ambrose Chan

**Name/Title:** Heng Fai Ambrose Chan, Chief Executive Officer, Alset Inc.

**Date:** 08/22/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Global Biomedical Pte. Ltd.

**Signature:** /s/ Heng Fai Ambrose Chan

**Name/Title:** Heng Fai Ambrose Chan, Director, Global Biomedical Pte. Ltd.

**Date:** 08/22/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Alset International Limited

**Signature:** /s/ Heng Fai Ambrose Chan

**Name/Title:** Heng Fai Ambrose Chan, Chief Executive Officer, Alset International Limited

**Date:** 08/22/2025